<DOC>
	<DOCNO>NCT01652560</DOCNO>
	<brief_summary>- The purpose study evaluate efficacy safety application bevacizumab combine neoadjuvant chemotherapy HER2-negative breast cancer .</brief_summary>
	<brief_title>Observational Studies Application Bevacizumab HER2-negative Breast Cancer Neoadjuvant Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>HER2negative breast cancer patient Without surgery Plans neoadjuvant chemotherapy HER2positive breast cancer patient Postoperative patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>HER2-negative breast cancer</keyword>
</DOC>